CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 161 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04496830
NCT04496830N/ACompleted
CompareCT.gov

Cerebrospinal Fluid-biomarkers-based Diagnostic and Prognostic Models for Multiple Sclerosis

Washington University School of Medicine·observational·Posted Aug 3, 2020·Updated Sep 11, 2025

In Brief

An observational study for Multiple Sclerosis. Completed, enrolled 161 participants across 1 site.

Detailed Summary

To determine if biomarker-based CSF testing is reliably detecting differences between patients with Multiple Sclerosis (MS), different MS-subtypes, and other central nervous system (CNS) diseases. This study will also look to identify biomarkers that could be used for the prediction, at the time of diagnosis, of the future disease clinical course and response to therapy. The SOMAscan assay will be used for CSF samples analysis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), University of Colorado, Denver, University of Ottawa, Montana State University

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 3, 2020
Enrollment StartJun 15, 2020
Primary CompletionNov 24, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.9 years ago